{"id":224519,"date":"2026-05-17T00:08:03","date_gmt":"2026-05-17T00:08:03","guid":{"rendered":"https:\/\/teknomers.com\/en\/antivirals-and-vaccines-current-projects-in-development-to-combat-hantavirus\/"},"modified":"2026-05-17T00:08:03","modified_gmt":"2026-05-17T00:08:03","slug":"antivirals-and-vaccines-current-projects-in-development-to-combat-hantavirus","status":"publish","type":"post","link":"https:\/\/teknomers.com\/en\/antivirals-and-vaccines-current-projects-in-development-to-combat-hantavirus\/","title":{"rendered":"Antivirals and Vaccines: Current Projects in Development to Combat Hantavirus"},"content":{"rendered":"\n<div data-section=\"articleBody\">\n<h2>Current Status of Hantavirus Treatments<\/h2>\n<p><strong>Currently, there is no drug specifically approved by the FDA or EMA for the treatment of hantavirus infections.<\/strong> This lack of treatment options extends to both Hantavirus Pulmonary Syndrome (HPS) and Hemorrhagic Fever with Renal Syndrome (HFRS). Current management remains solely supportive, focusing on intensive care. However, exciting developments are underway aimed at treating or immunizing against hantaviruses, which are primarily transmitted by rodents.<\/p>\n<h2>Diagnosis and Recent Outbreaks<\/h2>\n<p>Diagnostic efforts for hantavirus infections are centralized in Spain at the National Microbiology Center of the Carlos III Health Institute (ISCIII). Recently, Argentina sent supplies to various countries, including Spain, to conduct hantavirus diagnostic tests due to an outbreak linked to the MV Hondius tourist cruise, which departed from South America on April 1.<\/p>\n<h2>Pharmaceutical Advances: The Role of Moderna<\/h2>\n<p>In the realm of treatment, <strong>two key companies are attracting attention: Pfizer\/BioNTech and Moderna<\/strong>. Both companies have rapidly responded to the COVID-19 pandemic using their messenger RNA (mRNA) technology. While Pfizer has confirmed it is not currently working on hantavirus treatments, Moderna has announced preliminary research for a hantavirus vaccine. This research resulted in a notable surge in Moderna&#8217;s stock, reflecting market optimism regarding its potential. Moderna has collaborated with the U.S. Army Medical Research Institute of Infectious Diseases, focusing on countermeasures against various viral outbreaks.<\/p>\n<h3>Other Companies Leading the Charge<\/h3>\n<p>Several other companies are making strides in the development of antiviral treatments:<\/p>\n<ul>\n<li><strong>Atriva Therapeutics<\/strong> is working on zapnometinib, an antiviral MEK inhibitor currently in the preclinical phase targeting hantavirus. The FDA designated it as an orphan drug in 2022.<\/li>\n<li><strong>ICN Pharmaceuticals and Valeant<\/strong> have historical studies on ribavirin, an antiviral targeting HFRS. Although it has not received conventional FDA or EMA approval, it has been used off-label in certain Asian countries.<\/li>\n<li><strong>Ridgeback Biotherapeutics<\/strong> is exploring theoretical projects based on viral RNA, although not specifically focused on hantavirus.<\/li>\n<li><strong>SAB Biotherapeutics<\/strong> is testing its monoclonal antibody SAB-163 against hantavirus in preclinical trials.<\/li>\n<li><strong>Inovio Pharmaceuticals<\/strong> is conducting academic\/military trials for a DNA vaccine against the Hantaan and Puumala strains.<\/li>\n<\/ul>\n<h2>Research Initiatives in Academia<\/h2>\n<p>Academically, significant efforts are underway, particularly from <strong>Jay Hooper<\/strong>, a virologist at the U.S. Army Medical Research Institute of Infectious Diseases. He has dedicated three decades to developing a vaccine against various hantavirus species that can infect humans. Hooper highlights the military\u2019s longstanding interest in a hantavirus vaccine due to the risks posed to troops.<\/p>\n<p>Hooper&#8217;s team has advanced their research by developing hamster models similar to human HPS, allowing for more realistic testing scenarios. Preliminary Phase I clinical trials have been conducted for vaccines targeting strains like the Andes virus, where promising results have been observed.<\/p>\n<p>Additionally, researchers from <strong>the University of Bath (UK)<\/strong> are developing a new antigen against the Hantaan strain. Professor Asel Sartbaeva reported excellent immune responses from their vaccine, which needs to undergo clinical trials and regulatory approval before public distribution. Their work also aims to address the cold chain challenge by using a method of encapsulation to ensure thermal stability of the vaccine.<\/p>\n<h2>Conclusion: Hope for Hantavirus Vaccines and Treatments<\/h2>\n<p>The concerted efforts across pharmaceutical companies and academic institutions reflect a substantial commitment to combating hantavirus infections. While there remains much work to be done, the progress in vaccine development and antiviral treatments provides hope for future solutions to this serious health concern.<\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/teknomers.com\/category\/general\/\" rel=\"dofollow\">General News &#8211; 2<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Current Status of Hantavirus Treatments Currently, there is no drug specifically approved by the FDA or EMA for the treatment of hantavirus infections. This lack of treatment options extends to both Hantavirus Pulmonary Syndrome (HPS) and Hemorrhagic Fever with Renal Syndrome (HFRS). Current management remains solely supportive, focusing on intensive care. However, exciting developments are [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36400],"tags":[47375,3998,4233,2484,30286,1478,43623,4577],"class_list":["post-224519","post","type-post","status-publish","format-standard","hentry","category-health","tag-antivirals","tag-combat","tag-current","tag-development","tag-hantavirus","tag-projects","tag-science-and-health-health","tag-vaccines"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/224519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/comments?post=224519"}],"version-history":[{"count":0,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/224519\/revisions"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media?parent=224519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/categories?post=224519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/tags?post=224519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}